TY - JOUR T1 - Advances in pathogenesis and treatment of systemic sclerosis JF - Clinical Medicine JO - Clin Med SP - 55 LP - 60 DO - 10.7861/clinmedicine.16-1-55 VL - 16 IS - 1 AU - Christopher P Denton Y1 - 2016/02/01 UR - http://www.rcpjournals.org/content/16/1/55.abstract N2 - Systemic sclerosis is the most severe disease within the scleroderma spectrum and is a major medical challenge with high mortality and morbidity. There have been advances in understanding of pathogenesis that reflect the interplay between immune-inflammatory processes and vasculopathy and fibrosis. It can be regarded as a disease of connective tissue repair and this leads to organ-based complications. However the aetiology and triggering events remain to be elucidated. Treatment is available for many aspects of the disease although the available therapies are not curative and some complications remain very challenging, especially non-lethal manifestations such as fatigue, calcinosis and anorectal dysfunction. Immunosuppression is now established as a beneficial approach but balancing risk and benefit is vital, especially for powerful approaches such as autologous stem cell transplantation. ER -